Some of the greatest advancements in our society are from the brilliant minds of the STEM community. From medicine to mechanics, they are essential in developing a brighter, more innovative future. And although it’s still a small percentage (6.3 % of U.S. employment to be exact), the STEM workforce has a large impact on our economic growth and overall standard of living.
Because of the major role that STEM plays in the world’s rapid development, it’s important that we foster innovators in their early start-up phases, much like what our client Elsevier aims to do with its R&D initiative The Hive. The Hive is committed to promoting collaboration across the Pharma & Life Sciences industry by providing biotech and pharmaceutical start-ups with the opportunity to get recognized and advance their research.
Hive participants receive support, complimentary training, and access to Elsevier’s R&D solutions for 18 months, with the goal that they’ll innovate the way future treatments are researched and developed. This year’s participants include:
4P-Pharma bridges the gap between academic discovery and the pharma industry, helping mature early-stage technologies from the drug discovery level to clinical phase and commercialization. This French company was created in response to the urgent need for innovative therapeutics to enter the developing drug pipeline for cancer and inflammatory diseases.
Based in San Diego, Beacon Discovery is comprised of a team of scientists who have worked together for over a decade, leveraging their academic and pharma partnerships to advance research around translating G-Protein Coupled Receptors (GPCRs) into new therapeutics. The company’s mission is to efficiently identify and advance molecules targeting GPCRs from concept to clinic.
Exscientia is a UK company that uses AI systems to actively learn best practices from vast repositories of discovery data and design millions of novel, project-specific compounds. They are the first to automate drug design and are at the forefront of small molecule drug discovery.
LegoChem Biosciences is a South Korean company and the first Hive participant from Asia. With its expertise in medicinal chemistry, the company develops next generation Antibody-Drug Conjugates (ADC) utilizing its proprietary ADC platform ConjuAll™. It provides solutions for site-specific conjugation, linker stability and efficient payload release—which are three major unmet needs in ADC development.
Sigilon Therapeutics is a U.S. company based in Cambridge, MA that develops immune-privileged living therapeutic implants, which are for chronic diseases including hematologic, enzyme deficiency, endocrine and metabolic disorders. The aim of these implants is to provide long-term, more natural control for diseases that are currently treated with intermittent injection or infusion in order to restore health and improve quality of life.
Unum Therapeutics is a clinical-stage biopharmaceutical company, also from Cambridge, that’s focused on the development of novel immunotherapy products based on its universal Antibody-Coupled T-cell Receptor (ACTR). When combined with an antibody that recognizes a target on the surface of tumor cells, the ACTR receptor can direct an individual’s T-cells to kill the tumor. Unlike other approaches (such as CAR-T or TCR), Unum’s therapy is not restricted to a particular target and may be used in many different cancer types.
Want to learn more? You can read up on all of the latest Hive updates here.